

Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment

Dafina Janevska¹, Viktorija Chaloska-Ivanova¹, Vlado Janevski²

*1*University Clinic of Gastroenterohepatology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia; *2*University Clinic of Abdominal Surgery, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia

Abstract

Citation: Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. *OA Maced J Med Sci.* 2015 Dec 15; 3(4):732-736. <http://dx.doi.org/10.3889/oamjms.2015.111>

Key words: hepatocellular carcinoma; risk factors; diagnosis; management; review article.

Correspondence: Dr. Dafina Janevska, University Clinic of Gastroenterohepatology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia E-mail: dafina.janevska@gmail.com

Received: 20-Oct-2015; **Revised:** 23-Oct-2015; **Accepted:** 27-Oct-2015; **Online first:** 29-Oct-2015

Copyright: © 2015 Dafina Janevska, Viktorija Chaloska-Ivanova, Vlado Janevski. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing Interests: The authors have declared that no competing interests exist.

Hepatocellular carcinoma (HCC) is the most often primary cancer of the liver and is one of the leading causes of cancer-related death worldwide. The incidence of HCC has geographic distribution with the highest levels in countries with developing economies. Patients with hepatocellular carcinoma have poor prognosis despite the achievements in surgery techniques and other therapeutic procedures and it is a reason why continuous attention should be paid to this issue.

This article provides an overview of this disease based on an extensive review of relevant literature. The article summarizes the current risk factors, diagnosis, staging and the management of HCC.

Introduction

Liver cancer is the fifth most common cancer in men and the seventh in women [1]. World-wide incidence is between 250,000 and 1,000,000 new cases per year with a male-female ratio of about 4 or 5:1 [2]. Hepatocellular carcinoma (HCC) is the most often primary cancer of the liver, accounting for 85% till 90% of all primary liver cancers [3]. Its occurrence reaches a peak at approximately 70 years of age with a rarely occurrence before the age of 40 years. Major risk factors for HCC include chronic alcohol consumption, hepatitis B, hepatitis C and non-alcoholic fatty liver disease [3]. Other, less common causes are Wilson's disease, hereditary hemochromatosis, alpha1-antitrypsin deficiency, primary biliary cirrhosis and autoimmune hepatitis [4,

5]. The incidence of HCC in different regions of the world varies due to the incidence of the risk factors. Such countries are China, sub-Saharan Africa, Hong Kong and Taiwan with more than 15 cases per 100,000 populations per year [6]. Any agent leading to chronic hepatic injury and eventually cirrhosis has been associated with HCC. Although multiple etiologic factors are responsible for HCC, it has been made a significant progress in these past years in the understanding of the molecular mechanisms and the pathogenesis of this disease. This article provides an overview of this disease based on our extensive review of relevant literature. We will summarize the current risk factors, diagnosis, staging and the management of HCC.

Global variation of the incidence of HCC is in relation with the complex etiology of the neoplasm and the literature data depends on the evaluated region

and population, time in which the studies are done or the used methodologies.




Figure 1: Estimated Liver Cancer Incidence Worldwide in 2012: Men (<http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp>)

Relevant information can be provided by GLOBALCAN database maintained by the International Agency for Research on Cancer (Figure 1, 2) [7, 8].




Figure 2: Estimated Liver Cancer Incidence Worldwide in 2012: Women (<http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp>)

Risk factors

Almost 50% of all cases of HCC are associated with HBV infection and 25% are associated with HCV [9]. HBV is double-stranded DNA-containing virus that is able to integrate its DNA into the hepatic cells, act as a mutagenic agent and cause secondary chromosomal rearrangement and increasing genomic instability [10]. This is the reason why the risk of HCC development is 100-fold higher for patients who are infected with HBV in comparison with those who are not infected [11].

Major cause of HCC in Europe, Japan, Latin America and the United States is cirrhosis caused by hepatitis C virus infection and the annual incidence ranges from 2% to 8% [9, 10]. Generally HCV-infected patients have 17 fold higher risk of developing HCC than uninfected [11-13]. HCV is an RNA-containing virus, unable to integrate into the host genome and

therefore causes HCC by various indirect mechanisms such as alterations in apoptotic pathways and tumor formation [5, 14].

Obesity and diabetes mellitus have been correlated with increased risk of HCC [15, 16]. These patients have twice higher chance of developing HCC compared to those who are not obese and do not have diabetes [17]. Alcohol is another important risk factor for developing HCC with increasing as levels of alcohol intake rise [16]. Chronic consumption of alcohol from 40 to 60 grams of alcohol on a daily bases are highly associated with HCC [18]. Aflatoxin is a mycotoxin produced by *Aspergillus flavus* and related fungus that contaminates stored foods such as rice, corn, soybeans, and peanuts. In some regions of the world, especially in Asia and Africa, it is major risk factors of HCC [19]. Chronic exposure to aflatoxin is highly associated with HCC due to damaging the DNA of hepatic cells and causing mutation of the p53 tumor suppressor gene [20]. Mutations of other genes and chromosome aberrations are described in HCC also. Point mutation of the c-KRAS gene and co-amplification of the cyclin D1 gene are rare and are detected in 3% and 11% of HCCs respectively. Mutations of beta-catenin gene are detected in 26-41% of HCCs. Frequent allelic losses are reported at loci 1p, 4q, 5q, 8p, 11p, 13q, 16p, 16q and 17p and loss of heterozygosity (LOH) is reported on chromosome 16. Reduction of expression of p21WAF/CIP1 (universal CDK inhibitor), P16 protein loss, high level expression of transforming growth factor-beta (TGF-beta), high expression of DNA methyltransferase (DNMT1) mRNA are found in significant percentage of HCCs.

There is increased risk of developing HCC in several rare inherited disorders: glycogen storage disease, alpha-1-antitrypsin deficiency, metal storage disease and chronic cholestatic syndromes [21].

Diagnosis

In many patients, HCC is asymptomatic and when symptoms occur they are usually related to those of chronic liver disease such as yellowing of the skin and eyes, pain in the right upper abdominal side, swelling of the abdomen, weakness, weight loss, fever [19, 22]. Over the past decades more asymptomatic patient are being diagnosed as a result of the active surveillance and the increased awareness of HCC in high risk patients, especially in those with cirrhosis. Screening for HCC in these patients is recommended every six months [1] and most used tools are serum levels of alpha-fetoprotein (AFP) and ultrasound [22]. Also the role of the serum level of AFP not always correlate with the tumor growth and it has been showed that is less useful than previously tough [23].

Generally values over 400 ng/mL can confirm the diagnosis in 20% of HCC patients [19]. The diagnosis of HCC can be made by history, physical examination and using noninvasive imaging methods such as ultrasound, MRI and CT scan. Suspicious lesion in the liver detected by ultrasound usually requires additional imaging methods to confirm the diagnosis and to detect additional, smaller, lesions that previously were not seen. Specificity and sensitivity of the ultrasound depends on the size of the tumor, ability to detect tumors 3-5cm in diameter is 80-95% and 60-80% of tumors <1cm in diameter [5, 24]. Standard noninvasive diagnostic methods for diagnosing HCC are dynamic multiphasic multidetector-row CT (MDCT) and magnetic resonance imaging (MRI) [25]. Typical finding for HCC in contrast enhanced CT is arterial phase enhancement followed by loss of enhancement (washout) in the portal venous and delayed phases [26]. This image finding has a sensitivity of 90% and specificity of 95% for diagnosing HCC [26, 27]. Nodules less than 1 cm are difficult to assess and usually image-guided biopsy should be considered for these lesions [28]. This also should be done for focal hepatic masses with atypical imaging features or discrepant findings on CT and MRI, or for lesions detected in the absence of cirrhosis [1]. A negative result from the biopsy does not rule out malignancy and continuous surveillance and ultrasound check up is needed in intervals from 3 till 6 months until they grow in size or change their echo pattern [29].

Treatment

Tumor staging has an essential role in guiding and making decision for further treatment. There are many systems to use in patients with HCC, but today most effective and most used is the Barcelona Clinic Liver Cancer (BCLC) classification [30] (Figure 3).




Figure 3: Barcelona Clinic Liver Cancer (BCLC) classification. *PST – Performance Status Test

Performance status scale is developed by the Eastern Cooperative Oncology Group (ECOG) is

included in BCLC system and is used to evaluate the progression of diseases (Figure 4).

Grade	Description
0.	Fully active, able to carry on all pre-disease performance without restriction
1.	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
2.	Ambulatory and capable of all self-care but unable to bed or chair more than 50% of walking hours
3.	Capable of only limited self-care, confined to bed or chair more than 50% of walking hours
4.	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
5.	Dead

Figure 4: Performance status

Child-Turcotte-Pugh score which is also included in BCLC is used to assess the prognosis of chronic liver disease (Figure 5).

Parameter	Points assigned		
	1	2	3
Ascites	Absent	Slight	Moderate
Hepatic encephalopathy	None	Grade 1-2	Grade 3-4
Bilirubin micromol/L (mg/dL)	<34.2 (<2)	34.2-51.3 (2-3)	>51.3 (>3)
Albumin g/L (g/dL)	>35 (>3.5)	28-35 (2.8-3.5)	<28 (<2.8)
Prothrombin time			
Seconds over control	<4	4-6	>6
INR	<1.7	1.7-2.3	>2.3

CPT classification:
 Child A: score 5-6 (well compensated);
 Child B: score 7-9 (significant functional compromise);
 Child C: score 10-15 (decompensated)

Figure 5: Child-Turcotte-Pugh score

Using the BCLC system can help the doctor classify the patients with early-stage HCC, who may benefit from curative therapies and the patients with advanced-stage disease who would need palliative treatment. Sadly majority of patients present with advanced HCC at the time of diagnosis and are not candidate for curative therapies. Depending of the stage of the disease there are several therapeutic choices: surgical resection, percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and radioembolization [31].

First option for patients who have optimal profile according to BCLC staging system should be resection [32]. Surgical resection is the choice of treatment for patients with single nodules, no underlying cirrhosis and good liver function [33]. Treatment with PEI and RFA are optimal treatment option for patients with small tumours who are not candidates for surgical resection or liver transplantation [26]. Treatment with radiofrequency ablation demonstrated that complete ablation of lesions smaller than 2 cm is possible in more than 90% of cases, with a local recurrence rate of less than 1% [32, 34]. Survival rates after this treatment is 100% at first year and 98% at second year [1]. Standard treatment for the patients with intermediate-stage HCC is TACE. Patients with compensated liver function (Child B up to 8 points), with large single nodule (< 5 cm) or multifocal HCC without evidence of vascular invasion or extra hepatic spread are

considered candidates for TACE [33]. Also TACE plays an important role in the palliative treatment and it is a standard choice of treatment in patients with asymptomatic multinodular disease [35]. The prognosis of patients with HCC is poor in symptomatic patients in whom five-year survival rate is reported to be less than 5%. It is very poor in patients with AFP levels greater than 100ng/ml at the time of diagnosis, portal vein thrombosis and presence of p53 mutation. Long-term survival is reported only in patients with small, asymptomatic HCC (Table 1).

Table 1: Estimated Incidence, Mortality and Prevalence of liver cancer Worldwide in 2012. Estimated numbers (thousands)
<http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp>

	Men			Women			Both sexes		
	Cases	Deaths	5-year prev.	Cases	Deaths	5-year prev.	Cases	Deaths	5-year prev.
World	554	521	453	228	224	180	782	746	633
More developed regions	92	80	112	42	43	51	134	123	164
Less developed regions	462	441	341	186	182	129	648	622	469
WHO Africa region (AFRO)	25	24	17	14	13	9	39	37	26
WHO Americas region (PAHO)	40	35	35	23	23	18	63	58	53
WHO East Mediterranean region (EMRO)	20	19	12	10	9	6	29	28	18
WHO Europe region (EURO)	47	44	42	23	25	20	71	69	61
WHO South-East Asia region (SEARO)	55	52	33	25	24	15	80	77	48
WHO Western Pacific region (WPRO)	368	347	314	133	129	112	501	477	426
IARC membership (24 countries)	120	104	135	56	55	60	176	159	195
United States of America	23	17	21	8	7	7	30	24	27
China	293	282	220	101	101	71	395	383	291
India	17	17	8	10	10	5	27	27	13
European Union (EU-28)	36	32	33	16	17	14	52	48	47

The development of new drugs and types of therapy can improve the outcome of patients with hepatocellular carcinoma, but the key factor in management of HCC is still making a diagnosis in the very-early stages of disease and continuously surveillance of the patients with a high risk of HCC [1, 36, 37].

References

1. El-Serag HB. Hepatocellular Carcinoma. *N Engl J Med*. 2011;365:1118-27.
<http://dx.doi.org/10.1056/NEJMra1001683>
PMid:21992124
2. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. *Annals of Oncology*. 1997;8:117-136.
<http://dx.doi.org/10.1023/A:1008285123736>
PMid:9093719
3. El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. *Gastroenterology*. 2007;132:2557-2576
<http://dx.doi.org/10.1053/j.gastro.2007.04.061>
PMid:17570226

4. Heidelbaugh JJ., Bruderly M. Cirrhosis and chronic liver failure: Part I. Diagnosis and evaluation. *Am Fam Physician*. 2006;74:756-762
PMid:16970019
5. Sanyal AJ, Yoon SK, Lencioni R. The Etiology of Hepatocellular Carcinoma and Consequences for Treatment. *The Oncologist*. 2010;15(suppl 4):14-22.
<http://dx.doi.org/10.1634/theoncologist.2010-S4-14>
PMid:21115577
6. Munoz N, Bosch X. Epidemiology of hepatocellular carcinoma. In: Neoplasms of the Liver, Okuda, K, Ishak, KG (Eds), Springer, Tokyo 1989: p. 3.
7. Venook AP, Papatreou C, Furuse J, and Ladrón de Guevara L. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective *The Oncologist*. 2010;15:5-13.
8. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. *CA Cancer J Clin*. 2005;55:74-108.
<http://dx.doi.org/10.3322/canjclin.55.2.74>
PMid:15761078
9. Gurtsevitch VE. Human oncogenic viruses: Hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. *Biochemistry (Mosc)*. 2008; 73:504-513.
<http://dx.doi.org/10.1134/S0006297908050039>
10. Szabó E, Páska C, Kaposi Novák P. et al. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. *Pathol Oncol Res*. 2004; 10:5-11.
<http://dx.doi.org/10.1007/BF02893401>
PMid:15029254
11. Alan D, Herbst BA, and Reddy KR. Risk Factors for Hepatocellular Carcinoma. *Clinical Liver Disease*. 2012;1(6):??.
12. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. World Gastroenterology Organisation guideline. Hepatocellular carcinoma (HCC): a global perspective. *J Gastrointest Liver Dis*. 2010;19:311-317.
<http://dx.doi.org/10.1097/mcg.0b013e3181d46ef2>
13. Donato F, Tagger A, Gelatti U et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. *Am J Epidemiol*. 2002;155:323-331.
<http://dx.doi.org/10.1093/aje/155.4.323>
PMid:11836196
14. Sheikh MY, Choi J, Qadri I et al. Hepatitis C virus infection: Molecular pathways to metabolic syndrome. *Hepatology*. 2008;47:2127-2133.
<http://dx.doi.org/10.1002/hep.22269>
PMid:18446789
15. Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. *Ann Oncol*. 2009;20:353-357.
<http://dx.doi.org/10.1093/annonc/mdn565>
PMid:18723550
16. Ascha MS, Hanouneh IA, Lopez R, Abu-Rajab Tamini T, Feldstein AF, Zein NN. The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis. *Hepatology*. 2010;51(6): 1972-8.
<http://dx.doi.org/10.1002/hep.23527>
PMid:20209604
17. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. *Clin Gastroenterol Hepatol*. 2006;4:369-80.
<http://dx.doi.org/10.1016/j.cgh.2005.12.007>
PMid:16527702
18. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. *Am J Epidemiol*. 2002;155:323-31.
<http://dx.doi.org/10.1093/aje/155.4.323>
PMid:11836196
19. Raphael SW, Yangde Z, and YuXiang C. Hepatocellular Carcinoma: Focus on Different Aspects of Management ISRN

Oncology. 2012;Article ID 421673:12 pages.

20. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. *Nature*. 1991;350:429.

<http://dx.doi.org/10.1038/350429a0>

PMid:1672732

21. Hirohashi S, Blum HE, Ishak KG, Deugnier Y, Kojiro M, Laurent Puig P, Wanless IR, Fischer HP, Theise ND, Sakamoto M, Tsukuma H. Hepatocellular carcinoma in World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Digestive System IARC Press Lyon, 2000

22. El-Serag HB, Marrero JA, Rudolph L, and Reddy KR.

Diagnosis and treatment of hepatocellular carcinoma.

Gastroenterology. 2008;134(6):1752–1763.

<http://dx.doi.org/10.1053/j.gastro.2008.02.090>

PMid:18471552

23. Somi MH. Hepatocellular Carcinoma. *Hepatitis Monthly*. 2005; 5(3): 65-76

24. Ryder SD. British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. *Gut*. 2003; 52(suppl 3):iii1–iii8.

http://dx.doi.org/10.1136/gut.52.suppl_3.iii1

PMid:12692148 PMCID:PMC1867754

25. Bolog N, Andreisek G, Oancea I, and Mangrau A. CT and MR imaging of hepatocellular carcinoma. *Journal of Gastrointestinal and Liver Diseases*. 2011;20(2):181–189.

PMid:21725516

26. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. *Aliment Pharmacol Ther*. 2010; 15;31(4):461-76.

27. Marrero JA, Hussain HK, Nghiem HV, et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. *Liver Transpl*. 2005;11: 281–9.

<http://dx.doi.org/10.1002/lt.20357>

PMid:15719410

28. Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology*. 2005;42:1208-36.

<http://dx.doi.org/10.1002/hep.20933>

PMid:16250051

29. Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies. Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M, and Di Carlo I. *BioMed Research International*. 2014;Article ID 203693:15 pages.

30. Pons F, Varela M, and Llovet MJ. Staging systems in hepatocellular carcinoma. *HPB (Oxford)*. 2005; 7(1):35-41.

<http://dx.doi.org/10.1080/13651820410024058>

PMid:18333159 PMCID:PMC2023920

31. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2012; 56: 908-943.

<http://dx.doi.org/10.1016/j.jhep.2011.12.001>

PMid:22424438

32. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. *Hepatology*. 2011;53(3):1020–1022.

<http://dx.doi.org/10.1002/hep.24199>

PMid:21374666 PMCID:PMC3084991

33. Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. *World J Gastroenterol*. 2014;20(15):4115-4127.

<http://dx.doi.org/10.3748/wjg.v20.i15.4115>

PMid:24764650 PMCID:PMC3989948

34. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? *Hepatology*. 2008;47:82-89.

<http://dx.doi.org/10.1002/hep.21933>

PMid:18008357

35. Wang P, Sheng L, Mang G, Wang H, Huang X, Yan X, Yang X and Pei R. Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma.

Mol Clin Oncol. 2014; 2(2): 203–206.

PMid:24649333 PMCID:PMC3917780

36. Greten T F , Papendorf F, Bleck J S , Kirchoff T , Wohlbered T, Kubicka S , Klempnauer J , Galanskiand M, Manns M P.

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. *BJC*. 2005;92:1862–1868.

<http://dx.doi.org/10.1038/sj.bjc.6602590>

PMid:15870713 PMCID:PMC2361778

37. Hirohashi S, Blum HE, Ishak KG, Deugnier Y, Kojiro M, Laurent Puig P, Wanless IR, Fischer HP, Theise ND, Sakamoto M, Tsukuma H. Hepatocellular carcinoma in World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Digestive System IARC Press:Lyon, 2000.